Review: In chronic hepatitis C virus infection, oral direct-acting antivirals have high sustained virologic response | ACP Gastroenterology Monthly
A commentary in ACP Journal Club noted that while screening and treating all patients with chronic hepatitis C virus (HCV) would be cost-effective and probably cost-saving, some payers are still resistant.
ACP and the American Academy of HIV Medicine collaborate on new guide to hepatitis C testing | ACP Gastroenterology Monthly
The guide includes a summary of the latest testing recommendations; diagnostic, billing, and laboratory codes for testing; resources for referrals to HCV-experienced clinicians; and information on patient interactions, education, conversations, and
For postexposure prophylaxis, the hepatitis A vaccine is now preferred to immune globulin for all adults, including those older than 40 years of age, the Advisory Committee on Immunization Practices (ACIP) said.
The Advisory Committee on Immunization Practices released new recommendations, a CDC-funded study examined vaccination rates among patients who have HIV infection, and the FDA approved a new vaccine.
The CDC received more than 2,500 reports of hepatitis A infections associated with person-to-person transmission from multiple states from January 2017 to April 2018.
One study compared the hospitalization rate for autoimmune hepatitis among black, Latino, and Asian/Pacific Islander patients versus a reference rate among white patients, while another study retrospectively analyzed budesonide as a second-line
This month's quiz asks readers to evaluate a 58-year-old man at a follow-up visit for hepatitis C-related cirrhosis complicated by nonbleeding small esophageal varices and ascites.
8 weeks of ledipasvir/sofosbuvir may be effective for genotype 1 hepatitis C | ACP Gastroenterology Monthly
The therapy should be considered in patients with genotype 1 infection who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load below 6,000,000 IU/mL, a study found.
High HCV cure rate seen with FDA-approved direct-acting antiviral regimens | ACP Gastroenterology Monthly
Six of the direct-acting antiviral (DAA) regimens yielded sustained virologic response rates above 95% in patients who had hepatitis C virus (HCV) genotype 1 without cirrhosis, including those with HIV co-infection.
HCV treatment appeared successful for patients who hadn't responded to previous direct-acting antivirals, industry-funded study finds | ACP Gastroenterology Monthly
The study included two phase 3 trials: POLARIS-1, in which patients with chronic hepatitis C virus (HCV) had previously taken a regimen containing an NS5A inhibitor, and POLARIS-4, in which patients had previously received a direct-acting antiviral